BTK Inhibitors in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Review key strategies for integrating BTK inhibition into management of your patients with B-cell malignancies with downloadable slides from a live expert-led meeting series.

Share

Program Content

Activities

BTK Inhibition in B-Cell Malignancies
Leveraging BTK Inhibition Strategies in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2020

Expires: June 25, 2021

Faculty

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen administered by Scientific Affairs